Last reviewed 2026-05-28 · How we verify

BC106 insulin lispro

Adocia · Phase 1 active Small molecule ✓ Verified May 2026 Quality 0/100

BC106 insulin lispro is a Small molecule drug developed by Adocia. It is currently in Phase 1 development. Also known as: BioChaperone insulin lispro.

BC106 insulin lispro is a protein-based insulin receptor agonist, classified as an agonist. It was studied in a clinical trial (NCT01638325) to assess its pharmacokinetics, glucodynamics, safety, and other effects in healthy participants.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	BC106 insulin lispro
Also known as	BioChaperone insulin lispro
Sponsor	Adocia
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

BC106 insulin lispro CI brief — competitive landscape report
BC106 insulin lispro updates RSS · CI watch RSS
Adocia portfolio CI

Frequently asked questions about BC106 insulin lispro

What is BC106 insulin lispro?

BC106 insulin lispro is a Small molecule drug developed by Adocia.

Who makes BC106 insulin lispro?

BC106 insulin lispro is developed by Adocia (see full Adocia pipeline at /company/adocia).

Is BC106 insulin lispro also known as anything else?

BC106 insulin lispro is also known as BioChaperone insulin lispro.

What development phase is BC106 insulin lispro in?

BC106 insulin lispro is in Phase 1.

Manufacturer: Adocia — full pipeline
Also known as: BioChaperone insulin lispro

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing